Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02850575
Active, not recruiting Observational

Bone Fixation of Mpact Double Mobility Cup

NCT02850575 · tracked via the Priya Life Science France tracker
Sponsor
Medacta International SA
Phase
Observational
Started
2014-01
Last updated
2025-09-29

Condition(s) studied

Total Hip Replacement

Investigational drug(s) / intervention(s)

Mpact Double Mobility cup

Study summary

This study aims to evaluate long term fixation of the Mpact Double Mobility cup trough IMAGIKA technology.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * primary hip replacement * patients 18 to 80 years old * patients who accept the follow-up schedule Exclusion Criteria: * femoral neck fracture * patients requiring grafts * progressive local or systemic infections * patients presenting muscular deficiency, neuromuscular disease or vascular insufficiency of the involved limb * patients suffering from diseases that can compromize the recovery to independent mobility * patients with BMI \> 40 * patients with cognitive diseases that can compromize their participation in the study * patients living in geographical area not allowing the clinical follow-up to be performed * patients participating in other biomedical research * patients \<18 years old * patients \> 80 years old * pregnant or breast feeding women

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Clinique Générale Annecy France
Orthéo - Espace Fauriel Saint-Etienne France

More Medacta International SA trials in France

The Medacta International AMIStem-P Post-Marketing Surveillance Study Active, not recruiting
Multicenter Mpact DM France Recruiting
GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs Active, not recruiting
The Medacta GMK SpheriKA Post-Marketing Surveillance Study Recruiting
Clinical and Radiological Outcomes of Medacta Shoulder System FR Recruiting

Other trials for the same condition

Post-Market Observational Study of the HARMONY® Evolution Implants and Instruments Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02850575 on ClinicalTrials.gov ↗ ← All trials in France